Structure-based antigenic epitope and PEGylation improve the efficacy of staphylokinase

• Published in: Microbial cell factories Vol. 16; no. 1; pp. 197 - 10
• Main Authors: Xu, Yanying, Shi, Yueyuan, Zhou, Jianzhong, Yang, Wei, Bai, Lei, Wang, Shilei, Jin, Xin, Niu, Qiangsi, Huang, Ailong, Wang, Deqiang
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 14.11.2017; BioMed Central; BMC
• Subjects: Amino acids; Antibodies; Antigenic determinants; Antigens; Biological activity; Blood clots; Derivatives; Drug therapy; E coli; Epitopes; Experimentation; Fibrin; Health aspects; Heart attack; Heart attacks; Immunogenetics; Immunogenicity; Immunoglobulin G; In vivo methods and tests; Laboratory animals; Myocardial infarction; Peginterferon alfa-2b; PEGylation; Plasmids; Plates (structural members); Polyethylene glycol; Proteins; Staphylokinase; Studies; Therapeutic applications; Thrombolysis; U-Plasminogen activator; Urokinase; China; Staphylokinase; Immunogenicity; PEGylation

Staphylokinase (Sak) holds promise for use in thrombolytic therapy for acute myocardial infarction. However, its immunogenicity is a major disadvantage under clinical conditions. PEGylation has become a sophisticated method to decrease that immunogenicity. In this report, according predicted epitope...